UPC_APP_8340/2025

TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY AN INHIBITOR OF COMPLEMENT

Prozessuale & UnteranträgeSonstige prozessualeCourt of AppealGeneric application—

Übersicht Entscheidungen Zitate Dokumente Zeitverlauf

Parteien

Kläger

Alexion Pharmaceuticals, Inc.(AstraZeneca Group)

Vertreter: Elena Hennecke (Freshfields)

Beklagte

Samsung Bioepis NL B.V.

Vertreter: Peter Meyer (Simmons & Simmons)

Richter

Rian KaldenPresiding judge and judge-rapporteur
Patricia RombachLegally qualified judge
Ingeborg SimonssonLegally qualified judge

Patente

EP 3 167 888

CPC-Codes: A61P31/04, A61P25/18, A61P29/02, A61K39/395, A61K2039/505, A61P7/02, A61P25/26, A61P13/02, A61P15/10, A61P17/00, A61P7/00, A61P25/28…

Sektor: Organic Chemistry

Ausgang

Abgewiesen

Eingereicht: —

Erste Entscheidung: 19. Juni 2025

Sprache: —

Court of Appeal Panel 2 rejected Alexion Pharmaceuticals' application for rehearing (R. 245 RoP) of the earlier Court of Appeal order dismissing Alexion's appeal against the Hamburg Local Division's denial of provisional measures. Alexion had alleged fundamental procedural defects (new claim interpretation standard applied without being heard, and incorrect facts). The Court held that no fundamental procedural defect within the meaning of Art. 81(1)(b) UPCA / R. 247(c) RoP was established. Alexion ordered to bear Samsung's costs of the rehearing proceedings.